Skip to content

ADCIRCA® (tadalafil)

Behind you all the way.

Our team will work with your patients to identify any potential obstacles to access and affordability and how we may be able to assist with overcoming them.

Prescribe.

Electronic prescription

To get started, follow these simple steps:

  1. Follow the 3-step registration process
  2. Set up users for the account
  3. Go to the Start Now section on your dashboard
  4. Search for ADCIRCA®
ePrescribe

Coverage & Reimbursement

United Therapeutics Cares will educate your office on the benefits investigation process, including the requirements for prior authorizations and appeals. For patients, we’ll walk through the ins and outs of the insurance landscape and where their specific plan fits in.

Benefits investigations

We will initiate the benefits investigation process and educate your patients on navigating access and affordability challenges that may arise.

Benefits investigations

We will initiate the benefits investigation process and educate your patients on navigating access and affordability challenges that may arise.

Prior authorizations

Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll offer materials that can help educate you through the submission process and keep you informed of your patient’s status.

Prior authorizations

Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll offer materials that can help educate you through the submission process and keep you informed of your patient’s status.

Denials and appeals

If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.

Denials and appeals

If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.

Cost & Savings

If a patient is in need of financial assistance to cover the remaining out-of-pocket costs of their prescription, our team can provide information on options that may be available to them.

Co-pay assistance

If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Eligible patients pay as little as a $0 co-pay per prescription of ADCIRCA. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to the monthly maximum program benefit.*

Terms & Conditions *Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs, may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.

Co-pay assistance

If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Eligible patients pay as little as a $0 co-pay per prescription of ADCIRCA. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to the monthly maximum program benefit.*

Terms & Conditions *Patients must meet certain eligibility criteria to qualify for assistance. Patients receiving reimbursement under Medicare, Medicaid, VA, DoD (TRICARE), Indian Health Services, or similar federal or state programs, may not be eligible for some assistance. Some portion of this patient assistance may be administered by third-party patient assistance organizations. The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.

Patient Assistance Program (PAP)

If patients are uninsured or underinsured, they may meet the eligibility requirements for our Patient Assistance Program (PAP). For more eligibility information, you can contact United Therapeutics Cares at 844-864-8437.

Patient Assistance Program (PAP)

If patients are uninsured or underinsured, they may meet the eligibility requirements for our Patient Assistance Program (PAP). For more eligibility information, you can contact United Therapeutics Cares at 844-864-8437.

Additional financial resources

Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, there may be additional options for your patient to explore.

Additional financial resources

Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, there may be additional options for your patient to explore.

two people enjoy a laugh on the porch A man and woman laugh while sitting at a table together

Prescription Coordination

Once all benefits have been verified and financial assistance options are reviewed, we’ll walk your patient through getting set up with their Specialty Pharmacy. The Specialty Pharmacy will work directly with your patient to coordinate any final prescription details and confirm shipping preferences.

This is how Specialty Pharmacies work:

  1. Your Specialty Pharmacy will conduct a review of your patient’s insurance benefits.
  2. Your Specialty Pharmacy will confirm your patient’s medication coverage.
  3. Your Specialty Pharmacy will call your patient to review co-payment and insurance coverage.
  4. Shipments will be scheduled for delivery where it’s most convenient for your patient.

Our ADCIRCA® (tadalafil) Specialty Pharmacy network and Specialty Distributor

Accredo

CVS Specialty

CuraScript SD

Treatment Support

Beyond offering assistance with access, affordability, and prescription delivery, our team can help patients through questions they encounter as they begin their United Therapeutics treatment.

A doctor speaks with a patient while working on a laptop

Education specialists

Our in-house specialists are available to work with your patient one-on-one to help them better understand their condition and answer questions about their United Therapeutics therapy.

Get to know them
A woman sits outdoors with friends

Support organizations

There are organizations that understand your patient’s condition and have firsthand experience to help them through their treatment journey.

Explore the community

Looking for additional resources?

Patients deserve ready access to education and support. That’s why we offer a suite of resources, including treatment-specific brochures, to offer education anytime your patient may need it.

See all resources

For you:

  • ADCIRCA sample statement of medical necessity

  • ADCIRCA sample appeal letter

A woman reads on an electronic device

Browse our full resource library.

Explore resources

Please see below for Important Safety Information

CONTRAINDICATIONS

  • Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden, unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.
  • Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA

Important Safety Information for ADCIRCA® (tadalafil) tablets

CONTRAINDICATIONS

  • Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden, unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.
  • Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA

WARNINGS AND PRECAUTIONS

  • Cardiovascular: Patients who experience anginal chest pain after taking ADCIRCA should seek immediate medical attention
  • Hypotension: Phosphodiesterase 5 inhibitors (PDE-5is), including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, carefully consider whether patients with underlying cardiovascular disease could be adversely affected by such actions.
  • Worsening Pulmonary Vascular Occlusive Disease: Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these patients is not recommended
  • Vision/Hearing: Patients who experience a sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), or sudden decrease or loss of hearing after taking ADCIRCA should seek immediate medical attention
  • Prolonged Erection: In rare instances, men taking PDE-5is (including tadalafil) for ED reported an erection lasting more than four hours. Male patients who experience a prolonged erection should seek immediate medical attention

SPECIAL POPULATIONS AND POTENTIAL DRUG INTERACTIONS:

  • Special Populations (Pregnant or Expecting Pregnancy): Limited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.
  • Special Populations (Renal or Hepatic Impairment): The use of ADCIRCA is not recommended for patients with severe renal or hepatic impairment. Please see Full Prescribing Information for dosing recommendations for patients with mild to moderate renal or hepatic impairment
  • Potential Drug Interactions: The use of ADCIRCA with alpha blockers, blood pressure medications, or alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (light-headedness or fainting)
  • Potential Drug Interactions: Tadalafil is metabolized predominately by CYP3A in the liver. Use of ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir. For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with potent inducers of CYP3A, such as rifampin, should be avoided
  • Potential Drug Interactions: ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is used to treat erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). The safety and efficacy of combinations of ADCIRCA with Cialis or other PDE-5is have not been studied. Therefore, the use of such combinations is not recommended

ADVERSE REACTIONS

  • Adverse Reactions: The most common adverse event with ADCIRCA is headache (42% ADCIRCA vs 15% placebo). Other common adverse events (reported by ≥9% of patients on ADCIRCA and more frequent than placebo by 2%) include myalgia (14% vs 4%), nasopharyngitis (13% vs 7%), flushing (13% vs 2%), respiratory tract infection (13% vs 6%), extremity pain (11% vs 2%), nausea (11% vs 6%), back pain (10% vs 6%), dyspepsia (10% vs 2%), and nasal congestion (9% vs 1%)

ADC.ISI.HCP.SEP2020


For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.

Important Safety Information for ADCIRCA® (tadalafil) tablets

CONTRAINDICATIONS

  • Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden, unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.
  • Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA

WARNINGS AND PRECAUTIONS

  • Cardiovascular: Patients who experience anginal chest pain after taking ADCIRCA should seek immediate medical attention
  • Hypotension: Phosphodiesterase 5 inhibitors (PDE-5is), including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, carefully consider whether patients with underlying cardiovascular disease could be adversely affected by such actions.
  • Worsening Pulmonary Vascular Occlusive Disease: Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these patients is not recommended
  • Vision/Hearing: Patients who experience a sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), or sudden decrease or loss of hearing after taking ADCIRCA should seek immediate medical attention
  • Prolonged Erection: In rare instances, men taking PDE-5is (including tadalafil) for ED reported an erection lasting more than four hours. Male patients who experience a prolonged erection should seek immediate medical attention

SPECIAL POPULATIONS AND POTENTIAL DRUG INTERACTIONS:

  • Special Populations (Pregnant or Expecting Pregnancy): Limited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.
  • Special Populations (Renal or Hepatic Impairment): The use of ADCIRCA is not recommended for patients with severe renal or hepatic impairment. Please see Full Prescribing Information for dosing recommendations for patients with mild to moderate renal or hepatic impairment
  • Potential Drug Interactions: The use of ADCIRCA with alpha blockers, blood pressure medications, or alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (light-headedness or fainting)
  • Potential Drug Interactions: Tadalafil is metabolized predominately by CYP3A in the liver. Use of ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir. For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with potent inducers of CYP3A, such as rifampin, should be avoided
  • Potential Drug Interactions: ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is used to treat erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). The safety and efficacy of combinations of ADCIRCA with Cialis or other PDE-5is have not been studied. Therefore, the use of such combinations is not recommended

ADVERSE REACTIONS

  • Adverse Reactions: The most common adverse event with ADCIRCA is headache (42% ADCIRCA vs 15% placebo). Other common adverse events (reported by ≥9% of patients on ADCIRCA and more frequent than placebo by 2%) include myalgia (14% vs 4%), nasopharyngitis (13% vs 7%), flushing (13% vs 2%), respiratory tract infection (13% vs 6%), extremity pain (11% vs 2%), nausea (11% vs 6%), back pain (10% vs 6%), dyspepsia (10% vs 2%), and nasal congestion (9% vs 1%)

ADC.ISI.HCP.SEP2020


For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.